Urine metabolomic analysis in clear cell and papillary renal cell carcinoma: A pilot study.

摘要: Abstract Renal cell carcinoma (RCC) is one of the most lethal type tumors and twice more frequent in men than women. Initial symptoms are unspecific belated thus increasing mortality. Moreover, current diagnostic monitoring tools harmful for patient low-grade tumors. Therefore, novel minimally-invasive markers needed to diagnose monitor RCC patients. Urine represents ideal sample source non-invasive biomarkers RCC. In our study we aimed identify a urine metabolomic profile characteristic patients with purposes also prognostic value. By an UPLC-Q-ToF MS untargeted analysis, compared 23 (14 clear 9 papillary RCC) before surgery that healthy controls. Additionally, first time, these pre-nephrectomy 3 months year post-nephrectomy. We identified dysregulated variables by querying their exact mass against those presented Metlin Human Metabolome Database. Next, experimentally confirmed identity. Both subtypes showed similar patterns at all stages. 51 were significantly increased controls and, among them, 4 selected as potential discriminant metabolites between groups. could confirm identity p-cresol glucuronide describing time increase this metabolite (fold change = 2.922, P = .012). no differences occur post-nephrectomy RRC, while 188 Of 15 variables, isobutyryl- l -carnitine change = 2.098, P = .004) -proline betaine change = 3.328, P = .004), time. summary, have marker markers. When independent cohort patients, may improve diagnosis reducing procedures. Significance The high-radiation dose imaging techniques available renal Our analysis carried out samples from individual reveals These management use techniques.